AR060962A1 - Proceso de preparacion de derivados de quinazolina e intermediarios de sintesis - Google Patents
Proceso de preparacion de derivados de quinazolina e intermediarios de sintesisInfo
- Publication number
- AR060962A1 AR060962A1 ARP070102120A ARP070102120A AR060962A1 AR 060962 A1 AR060962 A1 AR 060962A1 AR P070102120 A ARP070102120 A AR P070102120A AR P070102120 A ARP070102120 A AR P070102120A AR 060962 A1 AR060962 A1 AR 060962A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- substituted
- cycloalkyl
- ring
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 15
- 239000001257 hydrogen Substances 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- -1 pmethoxyphenyl Chemical group 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un proceso para preparar un compuesto de formula (1) en donde A es heteroarilo de 5-miembros que contiene un átomo de nitrogeno y contiene opcionalmente 1, 2 o 3 átomos de nitrogeno adicionales; X es -NH- o -N(alquilo C1-4)-; m es 0, 1, 2 o 3; R1 es alquilo C1-6 sustituido con -OP(O)(OH)(OR) y opcionalmente sustituido además con 1 o 2 grupos alcoxi C1-4; R2 es hidrogeno o alquilo C1-6 opcionalmente sustituido con 1, 2 o 3 grupos alcoxi C1-4 o -S(O)pR8 (donde p es 0, 1 o 2), o R2 es un grupo seleccionado entre alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6 y cicloalquil C3-6-alquilo C1-4; o R1 y R2 junto con el átomo de nitrogeno al cual están unidos forman un anillo de 5 a 7 miembros cuyo anillo puede ser saturado, no saturado o parcialmente saturado, en donde el anillo se sustituye con un grupo seleccionado entre -OP(O)(OH)(OR) y alquilo C1-4 donde el alquilo C1-4 se sustituye con -OP(O)(OH)(OR), y donde el anillo se sustituye opcionalmente además con 1, 2 o 3 grupos alquilo C1-4; R3 es un grupo seleccionado entre hidrogeno, halo, ciano, nitro, alcoxi C1-6, alquilo C1-6; R4 es hidrogeno o un grupo seleccionado entre alquilo C1-4, heteroarilo, heteroarilC1-4alquilo, arilo y arilC1-4alquilo cuyo grupo está opcionalmente sustituido por 1, 2 o 3 sustituyente seleccionados entre metilo, etilo, ciclopropilo y etinilo; R5 se selecciona entre hidrogeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6 y cicloalquil C3-6-alquilo C1-4; R6 y R7se seleccionan en forma independiente entre hidrogeno, alquilo C1-4, cicloalquilo C3-6 y alcoxi C1-4; R8 es hidrogeno o alquilo C1-4; en donde R es un grupo protector lábil ante ácidos tal como ter-butilo, tritilo, pmetoxifenilo, bencilo o fenilo; que comprende ajustar el pH de una solucion de un compuesto de formula (2) en donde A, X, m, R3, R4, R5, R6 y R7 son como se definen para formula (1); R1' es alquilo C1-6 sustituido con -OP(O)(OR)2 y opcionalmente sustituido además con 1 o 2 grupos alcoxi C1-4; R2'es hidrogeno o alquilo C1-6 opcionalmente sustituido con 1, 2 o 3 grupos alcoxi C1-4 o -S(O)pR8 (donde p es 0, 1 o 2), o R2' es un grupo seleccionado entre alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6 y cicloalquil C3-6-alquilo C1-4; o R1' y R2' junto con el átomo de nitrogeno al cual están unidos forman un anillo de 5 a 7 miembros cuyo anillo puede ser saturado, no saturado o parcialmente saturado, en donde el anillo se sustituye con un grupo seleccionado entre - OP(O)(OR)2 y alquilo C1-4 en donde el alquilo C1-4 se sustituye con -OP(O)(OR)2, y donde el anillo se sustituye opcionalmente además con 1, 2 o 3 grupos alquilo C1-4: R8 es hidrogeno o alquilo C1-4; a un pH entre 5 y 6,5 a una temperatura de entre - 10°C y temperatura ambiente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0609617.6A GB0609617D0 (en) | 2006-05-16 | 2006-05-16 | Process & intermediate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060962A1 true AR060962A1 (es) | 2008-07-23 |
Family
ID=36637525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102120A AR060962A1 (es) | 2006-05-16 | 2007-05-16 | Proceso de preparacion de derivados de quinazolina e intermediarios de sintesis |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8063210B2 (es) |
| EP (1) | EP2019832B1 (es) |
| JP (1) | JP5249927B2 (es) |
| KR (1) | KR101463633B1 (es) |
| CN (1) | CN101443339B (es) |
| AR (1) | AR060962A1 (es) |
| AU (1) | AU2007251395B2 (es) |
| BR (1) | BRPI0712787A2 (es) |
| CA (1) | CA2650518C (es) |
| ES (1) | ES2392996T3 (es) |
| GB (1) | GB0609617D0 (es) |
| IL (1) | IL194861A0 (es) |
| MX (1) | MX2008014551A (es) |
| NO (1) | NO20084631L (es) |
| NZ (1) | NZ572204A (es) |
| TW (1) | TWI387601B (es) |
| WO (1) | WO2007132210A1 (es) |
| ZA (1) | ZA200809171B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2323215C2 (ru) * | 2001-12-24 | 2008-04-27 | Астразенека Аб | Замещенные производные хиназолина как ингибиторы ауроракиназы |
| EP2251343A1 (en) * | 2003-05-15 | 2010-11-17 | Arqule, Inc. | Imidazothiazoles as p38-kinase-inhibitors |
| CA2584368A1 (en) * | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| WO2007123892A2 (en) * | 2006-04-17 | 2007-11-01 | Arqule Inc. | Raf inhibitors and their uses |
| CN102317293A (zh) * | 2008-12-05 | 2012-01-11 | 艾科尔公司 | Raf抑制剂及其用途 |
| CN103664797A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN103435598B (zh) * | 2013-07-25 | 2015-08-05 | 苏州明锐医药科技有限公司 | 巴拉塞替的制备方法 |
| DK3046584T3 (en) | 2013-09-16 | 2017-10-02 | Astrazeneca Ab | THERAPEUTIC POLYMER NANOPARTICLES AND PROCEDURES FOR PREPARING AND USING THEREOF |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2323215C2 (ru) | 2001-12-24 | 2008-04-27 | Астразенека Аб | Замещенные производные хиназолина как ингибиторы ауроракиназы |
| US7022667B2 (en) * | 2002-07-03 | 2006-04-04 | Bristol-Myers Squibb Company | O-derivatized nocathiacin derivatives |
| CN1753889A (zh) * | 2002-12-24 | 2006-03-29 | 阿斯利康(瑞典)有限公司 | 喹唑啉化合物 |
| PL221490B1 (pl) * | 2002-12-24 | 2016-04-29 | Astrazeneca Ab | Pochodne fosfonooksychinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
| UA86470C2 (ru) * | 2002-12-24 | 2009-04-27 | Астразенека Аб | Производные фосфонооксихиназолина и их фармацевтическое применение |
| CL2004000797A1 (es) * | 2003-04-16 | 2005-05-27 | Astrazeneca Ab | Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc |
| JP2006526599A (ja) * | 2003-06-02 | 2006-11-24 | アストラゼネカ アクチボラグ | 癌のような増殖性疾患の治療のためのオーロラキナーゼインヒビターとしての（３−（（キナゾリン−４−イル）アミノ）−１ｈ−ピラゾール−１−イル）アセトアミド誘導体及び関連化合物 |
| GB0609619D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Combination |
-
2006
- 2006-05-16 GB GBGB0609617.6A patent/GB0609617D0/en not_active Ceased
-
2007
- 2007-05-14 NZ NZ572204A patent/NZ572204A/en not_active IP Right Cessation
- 2007-05-14 EP EP07732773A patent/EP2019832B1/en active Active
- 2007-05-14 BR BRPI0712787-1A patent/BRPI0712787A2/pt not_active IP Right Cessation
- 2007-05-14 CN CN2007800176933A patent/CN101443339B/zh not_active Expired - Fee Related
- 2007-05-14 AU AU2007251395A patent/AU2007251395B2/en not_active Ceased
- 2007-05-14 JP JP2009510529A patent/JP5249927B2/ja not_active Expired - Fee Related
- 2007-05-14 MX MX2008014551A patent/MX2008014551A/es active IP Right Grant
- 2007-05-14 CA CA2650518A patent/CA2650518C/en not_active Expired - Fee Related
- 2007-05-14 ES ES07732773T patent/ES2392996T3/es active Active
- 2007-05-14 KR KR1020087029568A patent/KR101463633B1/ko not_active Expired - Fee Related
- 2007-05-14 WO PCT/GB2007/001748 patent/WO2007132210A1/en not_active Ceased
- 2007-05-15 US US11/748,655 patent/US8063210B2/en not_active Expired - Fee Related
- 2007-05-16 TW TW096117466A patent/TWI387601B/zh not_active IP Right Cessation
- 2007-05-16 AR ARP070102120A patent/AR060962A1/es unknown
-
2008
- 2008-10-23 IL IL194861A patent/IL194861A0/en not_active IP Right Cessation
- 2008-10-24 ZA ZA200809171A patent/ZA200809171B/xx unknown
- 2008-11-04 NO NO20084631A patent/NO20084631L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2392996T3 (es) | 2012-12-17 |
| NO20084631L (no) | 2008-12-03 |
| WO2007132210A1 (en) | 2007-11-22 |
| MX2008014551A (es) | 2008-11-27 |
| KR101463633B1 (ko) | 2014-11-19 |
| JP2009537496A (ja) | 2009-10-29 |
| ZA200809171B (en) | 2009-11-25 |
| CA2650518A1 (en) | 2007-11-22 |
| GB0609617D0 (en) | 2006-06-21 |
| CA2650518C (en) | 2014-12-02 |
| US20070270384A1 (en) | 2007-11-22 |
| JP5249927B2 (ja) | 2013-07-31 |
| US8063210B2 (en) | 2011-11-22 |
| AU2007251395B2 (en) | 2011-01-06 |
| TWI387601B (zh) | 2013-03-01 |
| CN101443339B (zh) | 2012-07-04 |
| CN101443339A (zh) | 2009-05-27 |
| EP2019832A1 (en) | 2009-02-04 |
| IL194861A0 (en) | 2009-08-03 |
| TW200813080A (en) | 2008-03-16 |
| EP2019832B1 (en) | 2012-09-12 |
| KR20090008450A (ko) | 2009-01-21 |
| BRPI0712787A2 (pt) | 2012-09-11 |
| AU2007251395A1 (en) | 2007-11-22 |
| NZ572204A (en) | 2011-09-30 |
| HK1126221A1 (en) | 2009-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060962A1 (es) | Proceso de preparacion de derivados de quinazolina e intermediarios de sintesis | |
| AR060506A1 (es) | Compuestos organicos | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| AR049446A1 (es) | Preparacion de pregabalina ((s)-(+)-aminometil-5-metilhexanoico) y compuestos relacionados | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| BR122012009489B8 (pt) | processo para produzir 2-etóxi-1-{[2-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso | |
| AR048669A1 (es) | Derivados biciclicos de bisamida | |
| AR042668A1 (es) | Derivados de fosfonoxi quinazolinas y su uso farmaceutico | |
| AR023152A1 (es) | Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR060623A1 (es) | Compuestos derivados de 2-azetidinona y un metodo de preparacion | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| EA200801828A2 (ru) | Соединения 1,2,4,5-тетрагидро-3h-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения | |
| BRPI0817168A2 (pt) | "método para a preparação de um composto" | |
| AR079495A1 (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa | |
| HRP20080493T3 (hr) | Supstituirani kinolinski derivati kao mitotski inhibitori kinezina | |
| MA32192B1 (fr) | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique | |
| PE20020524A1 (es) | 7-oxo-piridopirimidinas como inhibidores de quinasas | |
| AR051373A1 (es) | Procedimiento para la preparacion de analogos aciclicos de nucleotidos de fosfonatos | |
| AR083861A1 (es) | OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
| AR041605A1 (es) | Compuesto 1- sustituido-4-nitroimidazol y metodo para preparar el mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |